Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 44 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Nivolumab (Opdivo) + Ipilimumab (Yervoy) for metastatic colorectal cancer patients with deficient DNA mismatch repair mechanism (dMMR) or high microsatellite instability (MSI-H)	Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Colon cancer	Gastrointestinal Cancer	2017	View \| Download
Neoadjuvant nivolumab with gemcitabine and cisplatin followed by adjuvant nivolumab for previously-untreated muscle-invasive bladder cancer	Cisplatin (Platinol) , Gemcitabine (Gemzar; gemcitabine hydrochloride) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Bladder cancer	Urological Cancer	2023	View \| Download
Cabozantinib with nivolumab and ipilimumab for previously untreated advanced or metastatic renal cell carcinoma	Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184) , Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Renal cell carcinoma (RCC)	Renal Cancer	2023	View \| Download
Bempegaldesleukin in combination with nivolumab for previously untreated unresectable or metastatic melanoma	Bempegaldesleukin (NKTR-214; BMS-986321; NEKTAR) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Melanoma	Skin Cancer	2022	View \| Download